UroGen Pharma Ltd. (URGN)
NASDAQ: URGN · Real-Time Price · USD
43.25
-0.70 (-1.59%)
Sep 18, 2026, 4:00 PM EDT - Market closed
UroGen Pharma Revenue
UroGen Pharma had revenue of $72.46M in the quarter ending June 30, 2026, with 199.22% growth. This brings the company's revenue in the last twelve months to $188.73M, up 100.27% year-over-year. In the year 2025, UroGen Pharma had annual revenue of $109.79M with 21.45% growth.
Revenue (ttm)
$188.73M
Revenue Growth
+100.27%
P/S Ratio
11.20
Revenue / Employee
$629,113
Employees
300
Market Cap
2.11B
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 109.79M | 19.39M | 21.45% |
| Dec 31, 2024 | 90.40M | 7.69M | 9.29% |
| Dec 31, 2023 | 82.71M | 18.36M | 28.52% |
| Dec 31, 2022 | 64.36M | 16.32M | 33.96% |
| Dec 31, 2021 | 48.04M | 36.24M | 307.17% |
| Dec 31, 2020 | 11.80M | 11.78M | 65,450.00% |
| Dec 31, 2019 | 18.00K | -1.11M | -98.40% |
| Dec 31, 2018 | 1.13M | -7.03M | -86.17% |
| Dec 31, 2017 | 8.16M | -9.37M | -53.46% |
| Dec 31, 2016 | 17.53M | - | - |
| Dec 31, 2015 | - | - | - |
| Dec 31, 2014 | - | - | - |
| Dec 31, 2013 | - | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Sarepta Therapeutics | 1.97B |
| Aurinia Pharmaceuticals | 311.51M |
| Vericel | 306.30M |
| Nuvation Bio | 169.90M |
| Ocular Therapeutix | 52.06M |
| Generate Biomedicines | 26.48M |
| Zenas BioPharma | 1.00M |
URGN News
- 4 days ago - UroGen Pharma Transcript: H.C. Wainwright 28th Annual Global Investment Conference - Transcripts
- 8 days ago - UroGen Pharma Transcript: 12th Annual Cantor Fitzgerald Global Healthcare Conference - Transcripts
- 9 days ago - UroGen Pharma Transcript: Wells Fargo 21st Annual Healthcare Conference - Transcripts
- 15 days ago - UroGen Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewsWire
- 17 days ago - UroGen Pharma to Present at Upcoming Investor Conferences - GlobeNewsWire
- 4 weeks ago - IntraGel Therapeutics and UroGen Pharma Sign Strategic Collaboration and Investment Agreements to Advance Sustained-Released Investigational Oncology Therapies - PRNewsWire
- 4 weeks ago - UroGen Announces Strategic Collaboration and Investment Agreements with IntraGel to Access Biodegradable Sustained-Release Gel Platform and Expand Oncology Pipeline - GlobeNewsWire
- 4 weeks ago - UroGen Pharma submits UGN-103 NDA to FDA - TheFly